Literature DB >> 2530185

Specific recognition by CD3- NK cells: a limiting dilution analysis of the frequency of alloreactive CD3- lymphocyte precursors.

G Melioli1, E Ciccone, M C Mingari, D Pende, O Viale, G Tambussi, A Merli, A Moretta, L Moretta.   

Abstract

Mesh：

Substances：

Year:  1989        PMID： 2530185     DOI： 10.1002/ijc.2910440715

Source DB:  PubMed          Journal:  Int J Cancer Suppl        ISSN： 0898-6924


× No keyword cloud information.
  4 in total

1.  Susceptibility or resistance to lysis by alloreactive natural killer cells is governed by a gene in the human major histocompatibility complex between BF and HLA-B.

Authors:  E Ciccone; M Colonna; O Viale; D Pende; C Di Donato; D Reinharz; A Amoroso; M Jeannet; J Guardiola; A Moretta
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

2.  Identification of four subsets of human CD3-CD16+ natural killer (NK) cells by the expression of clonally distributed functional surface molecules: correlation between subset assignment of NK clones and ability to mediate specific alloantigen recognition.

Authors:  A Moretta; C Bottino; D Pende; G Tripodi; G Tambussi; O Viale; A Orengo; M Barbaresi; A Merli; E Ciccone
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307

3.  A novel surface antigen expressed by a subset of human CD3- CD16+ natural killer cells. Role in cell activation and regulation of cytolytic function.

Authors:  A Moretta; G Tambussi; C Bottino; G Tripodi; A Merli; E Ciccone; G Pantaleo; L Moretta
Journal:  J Exp Med       Date:  1990-03-01       Impact factor: 14.307

Review 4.  Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation.

Authors:  Daniela Pende; Michela Falco; Massimo Vitale; Claudia Cantoni; Chiara Vitale; Enrico Munari; Alice Bertaina; Francesca Moretta; Genny Del Zotto; Gabriella Pietra; Maria Cristina Mingari; Franco Locatelli; Lorenzo Moretta
Journal:  Front Immunol       Date:  2019-05-28       Impact factor: 7.561
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.